Wealth Alliance Sells 16 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wealth Alliance lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 2.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 639 shares of the biopharmaceutical company’s stock after selling 16 shares during the quarter. Wealth Alliance’s holdings in Regeneron Pharmaceuticals were worth $525,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Norges Bank bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $697,296,000. Capital International Investors grew its holdings in Regeneron Pharmaceuticals by 37.3% during the second quarter. Capital International Investors now owns 2,956,615 shares of the biopharmaceutical company’s stock worth $2,124,326,000 after buying an additional 803,143 shares in the last quarter. Moneta Group Investment Advisors LLC raised its position in Regeneron Pharmaceuticals by 57,848.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock valued at $420,184,000 after buying an additional 581,379 shares during the last quarter. Bank of Montreal Can purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $116,520,000. Finally, Virginia Retirement Systems ET AL bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $83,318,000. 84.15% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Barclays increased their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Truist Financial reiterated a “buy” rating and issued a $1,045.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, December 18th. Deutsche Bank Aktiengesellschaft began coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 9th. They issued a “hold” rating and a $800.00 target price on the stock. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $915.00 to $914.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Finally, BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $939.05.

Get Our Latest Stock Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Up 0.7 %

Regeneron Pharmaceuticals stock opened at $953.42 on Friday. The firm has a 50 day simple moving average of $900.23 and a 200 day simple moving average of $841.51. The company has a current ratio of 5.69, a quick ratio of 5.74 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $973.99. The firm has a market capitalization of $103.88 billion, a price-to-earnings ratio of 27.44, a P/E/G ratio of 2.76 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period last year, the company earned $10.96 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.53 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,325,338. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, SVP Christopher R. Fenimore sold 1,680 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $844.01, for a total transaction of $1,417,936.80. Following the completion of the sale, the senior vice president now owns 17,070 shares of the company’s stock, valued at $14,407,250.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders sold 11,911 shares of company stock valued at $10,781,770 in the last quarter. 8.83% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.